Quantcast

Latest Cancer immunotherapy Stories

2014-04-28 08:31:49

-Proceeds to Support Advancement of Clinical Programs in Cancer Immunotherapy - SANTA MONICA, Calif., April 28, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the completion of a $50 million mezzanine private financing of convertible notes. Participants in the transaction included a syndicate of healthcare-dedicated...

2014-04-25 23:05:21

According to a new report from BCC Research the global market for cancer immunotherapies is expected to grow to nearly $67.9 billion by 2018, with a five-year compound annual growth rate (CAGR) of 14.7%. North American market, the fastest growing regional segment overall, is growing at a tremendous 15% CAGR. Wellesley, Mass. (PRWEB) April 25, 2014 BCC Research (http://www.bccresearch.com) reveals in its new report, CANCER IMMUNOLOGY AND ONCOLYTIC VIROLOGY: TECHNOLOGIES AND GLOBAL MARKETS,...

2014-04-24 08:33:57

Leading Cancer Immunotherapy Startup also Bolsters Leadership Team with Two Key Appointments SEATTLE, April 24, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, a biotechnology company focused on bringing forward novel immunotherapies for cancer, today announced the close of its Series A round with $176M in fully committed funds. http://photos.prnewswire.com/prnvar/20140113/DC45426LOGO Juno's initial funding of $120 million came predominantly from leading technology venture...

2014-04-07 16:25:44

Largest-ever gift to the Hutch promises to save lives by broadening the application of immunotherapy to lung, ovarian, pancreatic and colon cancers SEATTLE, April 7, 2014 /PRNewswire/ -- Fred Hutchinson Cancer Research Center scientists striving for new cancer cures -- and the patients who stand to benefit from them -- got an enormous boost today when the Bezos family committed $20 million to support the development of novel cancer immunotherapies. It is the largest single...

2014-04-03 08:29:54

Novel methodology leverages somatic hypermutation to rapidly generate humanized therapeutic antibodies with >97% human content SAN DIEGO, April 3, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, announced today that the U.S. Patent and Trademark Office (USPTO) has issued US Patent #8,685,897 broadly covering a novel approach to antibody humanization using somatic hypermutation. Leveraging key advantages of AnaptysBio's...

2014-03-31 08:30:41

Morgan Stanley's Head of Global Biotech Investment Banking Joins Leading Cancer Immunotherapy Startup SEATTLE, March 31, 2014 /PRNewswire/ -- Juno Therapeutics, a biotechnology company focused on bringing forward novel immunotherapies for cancer, announced today that Steve Harr, M.D., will join the company as its Chief Financial Officer and Head of Corporate Development. http://photos.prnewswire.com/prnvar/20140113/DC45426LOGO Harr currently serves as Managing Director and Head of...

2014-03-31 08:29:19

SANTA MONICA, Calif., March 31, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT(TM)) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for...

2014-03-27 08:34:30

BETHESDA, Md., March 27, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that Linda Powers, CEO, will present at the 4(th) Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference being held at the New York Academy of Medicine in New York City on Thursday, March 27 at 2:45 pm ET. During her presentation, Ms. Powers will provide an...

2014-03-26 12:28:30

WORCESTER, Mass. and TORONTO, March 26, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that Dr. Eric von Hofe, Ph.D., the President of its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be a member of a panel discussing immunotherapies for solid tumors at the Fourth Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference at the New York Academy of Medicine in New York City...

2014-03-19 20:21:22

-- Collaboration Focused on Cancer Immunotherapies for Pets -- KANSAS CITY, Kan., and PRINCETON, N.J., March 19, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced a global...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related